NCT02295475View on ClinicalTrials.gov

Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome

PHASE4CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

December 10, 2014

Primary Completion Date

April 30, 2020

Study Completion Date

March 31, 2022

Conditions

Antiphospholipid SyndromeThrombosis

Interventions

DRUG

Apixaban

DRUG

Warfarin

Trial Locations (2)

43210

The James Comprehensive Cancer Center, Columbus

84107

Intermountain Medical Center, Murray

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

University of Utah

OTHER

lead

Scott C. Woller, MD

OTHER

NCT02295475 - Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome | Biotech Hunter | Biotech Hunter